How to buy Merck-and-CoInc shares

Own Merck-and-CoInc shares in just a few minutes.

Picture not described

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Merck & Co., Inc (MRK) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$75.73 after a previous close of US$75.58. During the day the price has varied from a low of USD75.73 to a high of USD76.635. The latest price was USD76.36 (25 minute delay). Merck-and-CoInc is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Merck-and-CoInc

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Merck-and-CoInc. Find the share by name or ticker symbol: MRK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Merck-and-CoInc reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$74.11, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Merck-and-CoInc, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Merck-and-CoInc. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Merck-and-CoInc share price

Use our graph to track the performance of MRK stocks over time.

Merck-and-CoInc shares at a glance

Information last updated 2021-06-24.
OpenUS$75.73
HighUS$76.635
LowUS$75.73
CloseUS$76.36
Previous closeUS$75.58
Change US$0.78
Change % 1.032%
Volume 8,123,465
Information last updated 2021-06-24.
52-week rangeUS$67.2567 - US$81.1074
50-day moving average US$74.7707
200-day moving average US$74.3896
Target priceUS$93.02
PE ratio 27.5722
Dividend yield US$2.48 (3.28%)
Earnings per share (TTM) US$2.769

Compare share trading platforms to buy stock

Name Product Ratings Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (global stocks)
Finder's rating
★★★★★
US$0
US$10 per month if there’s been no login for 12 months
0.50%
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
Finder's rating
★★★★★
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
Finder's rating
★★★★★
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
Finder's rating
★★★★★
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Merck-and-CoInc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Merck-and-CoInc price performance over time

Historical closes compared with the last close of $76.36

1 week (2021-06-18) -0.33%
1 month (2021-05-25) 3.26%
3 months (2021-03-25) 5.20%
6 months (2020-12-24) -0.14%
1 year (2020-06-25) 4.51%
2 years (2019-06-25) -6.12%
3 years (2018-06-25) 31.02%
5 years (2016-06-24) 43.21%

Is Merck-and-CoInc under- or over-valued?

Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-CoInc's P/E ratio

Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Merck-and-CoInc shares trade at around 28x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Merck-and-CoInc's PEG ratio

Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5826. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Merck-and-CoInc's EBITDA

Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$18.6 billion.

The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.

Merck-and-CoInc financials

Revenue TTM US$48 billion
Operating margin TTM 31.42%
Gross profit TTM US$34.6 billion
Return on assets TTM 10.73%
Return on equity TTM 26.43%
Profit margin 14.63%
Book value 10.645
Market capitalisation US$193.3 billion

TTM: trailing 12 months

Shorting Merck-and-CoInc shares

There are currently 18.8 million Merck-and-CoInc shares held short by investors – that's known as Merck-and-CoInc's "short interest". This figure is 8% down from 20.5 million last month.

There are a few different ways that this level of interest in shorting Merck-and-CoInc shares can be evaluated.

Merck-and-CoInc's "short interest ratio" (SIR)

Merck-and-CoInc's "short interest ratio" (SIR) is the quantity of Merck-and-CoInc shares currently shorted divided by the average quantity of Merck-and-CoInc shares traded daily (recently around 12.0 million). Merck-and-CoInc's SIR currently stands at 1.57. In other words for every 100,000 Merck-and-CoInc shares traded daily on the market, roughly 1570 shares are currently held short.

However Merck-and-CoInc's short interest can also be evaluated against the total number of Merck-and-CoInc shares, or, against the total number of tradable Merck-and-CoInc shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merck-and-CoInc's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Merck-and-CoInc shares in existence, roughly 10 shares are currently held short) or 0.0075% of the tradable shares (for every 100,000 tradable Merck-and-CoInc shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Merck-and-CoInc.

Find out more about how you can short Merck-and-CoInc stock.

Merck-and-CoInc's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Merck-and-CoInc's total ESG risk score

Total ESG risk: 28.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Merck-and-CoInc's environmental score

Environmental score: 3.15/100

Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Merck-and-CoInc's social score

Social score: 15.55/100

Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Merck-and-CoInc's governance score

Governance score: 12.65/100

Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Merck-and-CoInc's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Merck & Co., Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.35
Total ESG percentile 47.16
Environmental score 3.15
Environmental score percentile 4
Social score 15.55
Social score percentile 4
Governance score 12.65
Governance score percentile 4
Level of controversy 3

Merck-and-CoInc share dividends

42%

Dividend payout ratio: 42.39% of net profits

Recently Merck-and-CoInc has paid out, on average, around 42.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.44% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.44% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.48 per share.

While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.

Merck-and-CoInc's most recent dividend payout was on 6 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 13 June 2021 (the "ex-dividend date").

Have Merck-and-CoInc's shares ever split?

Merck-and-CoInc's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-CoInc shares which in turn could have impacted Merck-and-CoInc's share price.

Merck-and-CoInc share price volatility

Over the last 12 months, Merck-and-CoInc's shares have ranged in value from as little as US$67.2567 up to US$81.1074. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4125. This would suggest that Merck-and-CoInc's shares are less volatile than average (for this exchange).

Merck-and-CoInc overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases). Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform